Common Contracts
6 similar Employment Agreement contracts by Rapport Therapeutics, Inc., Centessa Pharmaceuticals PLC, MeridianLink, Inc., Monte Rosa Therapeutics, Inc.
DB1/ 147697253.1 1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made by and between Centessa Pharmaceuticals LLC (the “Company”) and John Crowley, C.P.A. (the “Executive”) and is effective as of June 5, 2024 (the “Effective...Employment Agreement • August 13th, 2024 • Centessa Pharmaceuticals PLC • Pharmaceutical preparations • Massachusetts
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Rapport Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Cheryl Gault (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated June 29, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Rapport Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Abraham N. Ceesay (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated December 12, 2022 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • MeridianLink, Inc. • Services-prepackaged software • California
This Employment Agreement (“Agreement”) is made between MeridianLink, Inc., a Delaware corporation (including its successors and assigns, the “Company”), and Elias Olmeta (the “Executive”) and is effective as on the first day of the Executive’s employment with the Company, which is anticipated to be August 26, 2024 (the “Effective Date”).
SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Monte Rosa Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Employment Agreement (this “Agreement”) is made between Monte Rosa Therapeutics, Inc., a Delaware corporation (the “Company”), and Jennifer Champoux (the “Executive”) and is effective as of May 28, 2024 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 8th, 2024 • Rapport Therapeutics, Inc. • Pharmaceutical preparations • Michigan
This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Troy Ignelzi (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated October 24, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
